An Open-label, Phase 1 Study of the Relative Bioavailability, Food Effect, Safety and Tolerability of an Oral Solution Formulation of MLN8237 in Patients With Advanced Solid Tumors.

Trial Profile

An Open-label, Phase 1 Study of the Relative Bioavailability, Food Effect, Safety and Tolerability of an Oral Solution Formulation of MLN8237 in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2015

At a glance

  • Drugs Alisertib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Millennium
  • Most Recent Events

    • 12 Dec 2015 Pharmacokinetic results of this study (n=24) published in the Drugs in R and D.
    • 18 Jun 2012 Actual patient number (53) added as reported by ClinicalTrials.gov.
    • 18 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top